G1 Therapeutics, Inc., a clinical-stage oncology company, has officially appointed Barclay (Buck) Phillips as chief financial officer as well as senior vice president of Corporate Development, and Chandra Lovejoy as vice president of Global Regulatory Affairs.

Mr. Phillips joins G1 with more than 25 years of capital markets, financial strategy, and business development experience in life sciences and venture capital. In his most recent role, he served as senior vice president, chief financial officer, and treasurer of Novavax.

Ms. Lovejoy has nearly 20 years of experience in global drug development, specializing in oncology. Most recently, she led global regulatory strategy as senior vice president, Global Regulatory Affairs and head of quality at Sierra Oncology.

“We are pleased to welcome Buck and Chandra to the G1 team. Buck has strong cross-functional expertise having led financial strategy and reporting for two publicly traded biotechnology companies, as well as a deep understanding of the equity capital markets from his time as an investor. In addition, we look forward to leveraging Chandra’s expertise in global regulatory strategy and clinical trial design as we advance our therapies toward multiple data readouts in 2018, and expand our pipeline through additional studies.”